Briefing Numinus Wellness Inc Psychedelics

Numinus Wellness Parts With Chief Strategy Officer, Issues 2.0 Million Shares With Separation

Numinus Wellness Inc. (TSXV: NUMI) announced on Thursday that its Chief Strategy Officer Stacey Wallin is leaving the company. The responsibilities of the position have been currently transitioned “across [the firm’s] leadership team”. As part of the separation agreement, the company is issuing to Wallin 2.0 million common shares from treasury. Based on the company’s …

Briefing Compass Pathways Psychedelics

Compass Pathways Granted Its Tenth Overall Patent Related To Psilocybin

Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted a fifth patent in the United States. The patent is related to what is referred to as crystalline psilocybin. More specifically, the patent covers methods of treating treatment-resistant depression through the use of crystalline psilocybin. The patent also covers the …

Analyst Estimate Briefing Compass Pathways Psychedelics

Compass: Canaccord Reiterates $80 Price Target After Study Data

Earlier this month, Compass Pathways (Nasdaq: CMPS) announced positive topline results and its key findings in its Phase 2b clinical trial of COMP360 psilocybin therapy to treat depression. The study reportedly “achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically significant and clinically relevant reduction in …

Biotech Briefing Psychedelics Revive Therapeutics

Revive Therapeutics Announces Research Collaboration Agreement For Psilocybin Microneedle Patch

Revive Therapeutics (CSE: RVV) announced today that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (CSE: PHRM). The agreement seeks to evaluate delivering psilocybin with the latter’s microneedle patch technology for treating neuropsychiatric disorders. PharmaTher is conducting studies with MicroDose-MN–a biocompatible and biodegradable gelatin methacryloyl microneedle patch to deliver psilocybin. The studies …

Briefing News Psyched Wellness Psychedelics

Psyched Wellness Sees Amanita Muscaria Approved As Medicinal Organism By Health Canada

After more than a years worth of development work, Psyched Wellness (CSE: PSYC) this morning had a major announcement. The company has seen the Amanita Muscaria mushroom added to the Natural Health Products Ingredients Database of Canada. The approval follows the submission by Psyched for the approval of the mushroom for use as an approved …

Briefing Mind Cure Health Psychedelics

Mindcure Ends Fiscal Q1 2022 With $15.6 Million Cash & Cash Equivalents, $2.8 Million Net Loss

Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended August 31, 2021. The firm ended the quarter with a $2.8 million net loss compared to fiscal Q1 2021’s net loss of $0.3 million. Among the company’s expenses for the quarter include $1.0 million in consulting fees and payroll, $0.2 …

Briefing KetamineOne Capital News Psychedelics

KetamineOne Announces Two Studies Focused On PTSD, Depression

KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced the inaugural launch of not one, but two research studies. The studies will be centered around that of PTSD and depression. The first study, classified as a single arm, open label study of persons with PTSD, will examine persons undergoing …

Briefing Psyched Wellness Psychedelics

Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1. The next round of pre-clinical trials focuses on the beneficial or adverse …